Category Archives: Business and Investments

Latest From Business and Investments

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO CEO Company Snapshot: Conatus Pharmaceuticals

Conatus-Pharma

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February. The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. What is your company’s lead product or technology? Conatus’s lead product is emricasan, a first-in-class oral Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Hill’s Congress Blog: Innovation in medicine isn’t optional – it’s imperative

TheHill

Earlier this week, The Hill’s Congress Blog posted an op-ed penned by Andrew von Eschenbach and Paul Howard entitled, “Innovation in medicine isn’t optional – it’s imperative” highlighting the importance of encouraging innovation and preserving incentives for drug development. The authors recommend increased cooperation and collaboration between industry, academia, and regulators, in addition to recognition by the federal government that ‘a vibrant life-sciences industry will generate higher national productivity, lower total health care costs, and Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

Bioscience’s Bright Spots

2014_BIO

According to Business Xpansion Journal, biotech is still big business and partnerships lead to profit. And BIO agrees. “In the past several years, it has become more important than ever for those in our industry to form partnerships and collaborations,” says Fritz Bittenbender, executive vice president, external affairs, BIO. “Big pharma, small biotechs, universities, investors, patient groups, the NIH – everyone is recognizing that success is only achieved by working with others. One place we’ve seen this Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,